CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) will report third quarter 2004 financial
results on Tuesday, November 9, 2004 before the open of U.S. financial
markets. In connection with this announcement, TKT will host a conference
call and live audio webcast on November 9, 2004 at 10:00 a.m. Eastern Time.
Participants may access the call by dialing (719) 457-2618. This call will
also be broadcast live over the Internet at http://www.tktx.com under the
Investor Information section.
A replay of this conference call will be available for two weeks,
beginning Tuesday, November 9, 2004 at 1:00 p.m. Eastern Time by dialing (719)
457-0820 and using the access code 953576. In addition, a replay of the
webcast will be archived on the TKT website in the Investor Information
section.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. Outside its
focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Sanofi-Aventis SA.
CONTACT:
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Manager of Transkaryotic Therapies, Inc., +1-617-349-0205
|
